版本:
中国

BRIEF-Fennec announces launch of European named patient programme for sodium thiosulfate for pediatric patients with standard risk hepatoblastoma

May 30 Fennec Pharmaceuticals Inc

* Fennec announces launch of European named patient programme for sodium thiosulfate for pediatric patients with standard risk hepatoblastoma

* Says Fennec will make STS available for pediatric patients with standard risk hepatoblastoma

* Says pending favorable siopel 6 results, Fennec intends to file NDA/MAA submissions for STS

* Says siopel 6 initial results will be available in Q4 of 2017

* Fennec Pharmaceuticals says Fennec's NPP is intended to make STS available to patients before commercial availability in certain countries Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐